Advertisment

Enhancing Liquid Biopsy for Non-invasive Tumor Detection: A Leap Forward in Oncology

author-image
Zara Nwosu
New Update
NULL

Enhancing Liquid Biopsy for Non-invasive Tumor Detection: A Leap Forward in Oncology

Advertisment

The advent of liquid biopsies has revolutionized the field of oncology, providing a non-invasive method for detecting tumors. This approach relies on analyzing circulating tumor DNA (ctDNA) in a blood sample to identify the presence of any malignancies. However, recent advancements have further refined this technique, boosting the concentration of ctDNA in vivo, thus enhancing the sensitivity of these biopsies. This article will delve into the details of these advancements and their potential implications in the clinical setting.

Advertisment

Injectable Priming Agents to Boost ctDNA Concentration

A recent study published in Nature Biotechnology has introduced two injectable priming agents that temporarily increase the concentration of ctDNA in vivo. This results in amplified sensitivity of liquid biopsies for non-invasive tumor detection. The authors have developed a nanoparticle that influences macrophages in the liver, which are responsible for clearing ctDNA from the bloodstream. This action leads to a tenfold increase in ctDNA recovery from blood samples, as observed in mice post-injection.

Enhancing Sensitivity of Liquid Biopsies

Advertisment

This two-part priming strategy aims to improve liquid biopsies' sensitivity for cancer detection and monitoring. The strategy involves developing injectable agents to slow down the clearance of cell-free DNA (cfDNA) from the body. This enables more comprehensive tumor molecular profiling and significantly enhances the sensitivity for detecting small tumors. This approach has shown promising results in preclinical cancer models, particularly in situations where the tumor DNA level is very low at baseline. The next steps involve further testing for safety and efficacy in preclinical settings and eventually in first-in-human trials before translating the technology into clinical use.

Liquid Biopsy in Lung Cancer and Glioblastoma

Dr. Atocha Romero and Dr. Inmaculada Ibáñez de Cáceres provide detailed insights into the use of liquid biopsies, specifically ctDNA, for tumor detection in lung cancer and glioblastoma. They discuss the clinical utility of liquid biopsy, the use of digital PCR for ultra-rare variant quantification, the challenges and potential of using extracellular vesicles (EVs) for DNA epigenetic profiling, and the future advancements in liquid biopsy for early cancer detection and personalized medicine.

Advertisment

Collaborative Efforts to Improve Liquid Biopsy

The GEDiCube and Cyclomics collaboration is a prime example of the efforts to advance liquid biopsy for cancer detection. Cyclomics has developed a diagnostic method for monitoring early cancer recurrence, CyclomicsSeq, which uses a ctDNA detection assay based on 'Oxford Nanopore sequencing.' This method ensures high detection accuracy and is expected to enable reliable, fast, and ultra-sensitive early/recurrence cancer detection. The integration of Cyclomics whole genome data into GEDiCube’s AI/machine learning platform aims to bring early detection of cancer to its inflection point.

In conclusion, the enhanced sensitivity of liquid biopsies through the development of injectable priming agents marks a significant advance in oncology. The potential of this technology to improve non-invasive tumor detection and monitoring, particularly in cases where tumor DNA levels are low, is promising. As further safety and efficacy tests are conducted and the clinical utility of these advancements continues to be explored, we move a step closer to the future of personalized medicine and early cancer detection.

Advertisment
Chat with Dr. Medriva !